Allergan Inc. Updated Company Profile : Outlook, Strategy and Forecasts

NEW YORK--(Business Wire)--Reportlinker.com announces that a new market research report
related to the Pharmaceutical industry is available in its catalogue.

Allergan Inc.: Company Profile

To order that report:

www.reportlinker.com/p073696/Allergan-Inc-Company-Profile.html

For more information, contact Nicolas by email
nbo@reportlinker.com , by phone +33 4 37 65 17 03.

This analysis examines the historical and forecast performance for
Allergan in the ethical pharmaceutical sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and
assessment of financial performance, with 1-6 year sales forecasts for
key drugs. An interactive forecasting and analysis tool provides
continually updated quantitative and qualitative information.

Assess Allergan's continued dependence on its Botox franchise.
Analyze how this franchise underscores Allergan's high biologics
dependency versus its Mid Pharma peers.

CHAPTER 1 EXECUTIVE SUMMARY 2

Key findings 2

Historical and forecast prescription pharmaceutical sales
performance 3

Therapeutic strategy 5

Launch and expiry outlook 8

Externalization, geographic and molecule type strategies 10

Externalization strategy 11

Geographic strategy 12

Molecule type strategy 12

SWOT analysis 13

Strengths 13

Weaknesses 14

Opportunities 15

Threats 17

CHAPTER 2 CORPORATE HISTORY 21

Key findings 21

Background 22

Key corporate developments 22

M&A history 23

Acquired by SmithKline Beckman 24

Allergan Spun-out from SmithKline Beckman 24

Acquisition of Oculinum 24

Divestment of Allergan Humphrey 24

Divestment of contact lens businesses 24

Five acquisitions were made in and around 1995 25

Allergan Specialty Therapeutics (ASTI) spun-out 25

Allergan Specialty Therapeutics (ASTI) re-acquired 25

Bardeen Sciences set-up 25

Advanced Medical Optics (AMO) spun-out 26

Bardeen Sciences acquired 26

Oculex acquired 26

Acquisition of Inamed 26

Groupe Corneal Laboratoires acquired 27

EndoArt acquired 27

Agreement to acquire Esprit Pharma 27

Current corporate structure 28

Allergan Medical 29

Current management team 30

CHAPTER 3 HISTORICAL PERFORMANCE 31

Key findings 31

Introduction 32

Revenue and growth rate analysis, 2001-06 32

Revenue and growth rate vs. peer set 33

Product analysis, 2001-06 35

Growth drivers 35

Botox 35

Restasis 37

Lumigan franchise 37

Alphagan franchise 37

Operating revenue and cost analysis, 2001-06 38

Operating revenue/cost analysis 40

CHAPTER 4 FORECAST PERFORMANCE 42

Key findings 42

Introduction 43

Revenue and growth rate, 2006-12 43

Product analysis, 2006-12 45

Dependence on Botox is set to increase further still 47

Pipeline products contribute little to 2012 sales 47

Growth drivers 49

Botox is set to provide the majority of Allergan's prescription
pharmaceutical sales growth 49

Restasis is forecast to be Allergan's fastest growing product 49

Posurdex represents the company's greatest pipeline contribution
50

Lumigan franchise is set to grow with the prostaglandin class 50

Growth resistors 51

Alphagan franchise is set to decline from 2010 51

Key strategic products 52

Therapy area analysis, 2006-12 54

CNS 56

Other 57

Therapy area focus 58

Launches and expires analysis, 2006-12 61

Launch portfolio 61

Forecast to launch in 2008, Posurdex is Allergan's key pipeline
product 62

Trivaris must demonstrate benefits that warrant the risks 62

Memantine is not considered likely to succeed 62

Combigan and Ganfort are not forecast to launch in the US 63

Core portfolio 65

Competition to Botox will remain limited across 2006-12 66

Other 'core' products are not likely to significantly disappoint
over 2006-12 67

Expiry portfolio 68

Zorac is not expected to face generic competition until H2 2011 68

Alphagan franchise sales will be pulled down by genericization 68

Launch/core/expiry configuration 70

Externalization analysis, 2006-12 73

Geographic analysis, 2006-12 79

Molecule type analysis, 2006-12 83

CHAPTER 5 KEY PRODUCTS AND COMPETITORS 88

Key findings 88

Overview 89

Ophthalmology 90

Alphagan franchise 90

Overview 90

Sales forecast 91

Newsflow 92

Competitive landscape 93

Future growth 97

Restasis 100

Overview 100

Sales forecast 101

Newsflow 102

Competitive landscape 103

Future growth 103

Lumigan franchise 107

Overview 107

Sales forecast 108

Newsflow 109

Competitive landscape 110

Future market growth 111

Posurdex 114

Overview 114

Sales forecast 115

Newsflow 116

Competitive landscape 117

Posurdex offers significant benefits over the standard of care 118

Future growth 118

CNS 121

Botox 121

Overview 121

Sales forecast 122

Newsflow 123

Competitive landscape 124

Future sales 125

R&D pipeline 129

CHAPTER 6 APPENDIX 131

IMS vs. company-reported data reconciliation 131

References 133

Abbreviations 133

List of Tables

Table 1: Allergan Corporate Executive Committee 30

Table 2: Peer set overview 33

Table 3: Operating revenue/cost analysis ($m), 2001-06 38

Table 4: Operating cost ratio analysis (% of total revenues),
2001-06 40

Table 5: Product portfolio overview, sales ($m), 2006-12 45

Table 6: Therapy area overview, sales ($m), 2006-12 54

Table 7: Launch portfolio overview, sales ($m), 2006-12 61

Table 8: Core portfolio overview, sales ($m), 2006-12 65

Table 9: Expiry portfolio overview, sales ($m), 2006-12 68

Table 10: Externally developed portfolio, 2006-12 ($m) 73

Table 11: Molecule type overview, sales ($m), 2006-12 83

Table 12: Key products overview 89

Table 13: Alphagan P: overview 90

Table 14: Alphagan franchise: sales forecast ($m), 2006-12 91

Table 15: Alphagan franchise: newsflow 92

Table 16: Restasis: overview 100

Table 17: Restasis: sales forecast ($m), 2006-12 101

Table 18: Restasis: newsflow 102

Table 19: Lumigan: overview 107

Table 20: Lumigan franchise: sales forecast ($m), 2006-12 108

Table 21: Lumigan franchise: newsflow 109

Table 22: Posurdex: overview 114

Table 23: Posurdex: sales forecast ($m), 2006-12 115

Table 24: Posurdex: newsflow 116

Table 25: Botox: overview 121

Table 26: Botox: sales forecast ($m), 2006-12 122

Table 27: Botox: newsflow 123

Table 28: Allergan's R&D pipeline (Phase I-registration) 129

Table 29: Allergan's label expansion pipeline (Phase
I-registration) 130

List of Figures

Figure 1: Historical and forecast prescription pharmaceutical
sales performance (% CAGR), Allergan and Mid Pharma peer set 3

Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2006 5

Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Allergan 8

Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 9

Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006 10

Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012 11

Figure 7: SWOT analysis of Allergan 13

Figure 8: M&A/divestment history 23

Figure 9: Current corporate structure 28

Figure 10: Revenue & growth rate (prescription pharmaceutical
sales) ($m), 2001-06 32

Figure 11: Prescription pharmaceutical revenue ($m) and growth
rate (%) vs. peer set, 2001-06 34

Figure 12: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06 35

Figure 13: Operating revenue/cost analysis ($m), 2001-06 39

Figure 14: Operating cost ratio analysis (% of total revenues),
2001-06 41

Figure 15: Prescription pharmaceutical sales ($m) and growth rate
(%), 2006-12 43

Figure 16: Top five products by sales ($m), 2006 46

Figure 17: Top five products by sales ($m), 2012 47

Figure 18: Growth drivers and resistors by product, 2006-12 48

Figure 19: Key strategic products, sales ($m), 2006-12 52

Figure 20: Pharmaceutical sales by therapy area ($m), 2006-12 55

Figure 21: Growth drivers and resistors by therapy area (%),
2006-12 56

Figure 22: Prescription pharmaceutical sales by therapy area (%),
2006-12 58

Figure 23: Therapy area focus compared with peer set (% total
prescription pharmaceutical sales), 2006 59

Figure 24: Therapy area focus compared with peer set (% total
prescription pharmaceutical sales), 2012 60

Figure 25: Launch schedule, sales ($m), 2006-12 64

Figure 26: Core products sales growth ($m), 2006-12 67

Figure 27: Expiry schedule, sales ($m), 2006-12 69

Figure 28: Launch, core and expiry, sales ($m), 2006-12 70

Figure 29: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Allergan 71

Figure 30: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 72

Figure 31: Externalization dependency, sales ($m), 2006-12 75

Figure 32: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12 76

Figure 33: Externalization dependency vs. peer set, % total sales,
2006 77

Figure 34: Externalization dependency vs. peer set, % total sales,
2012 78

Figure 35: Geographical sales breakdown ($m), 2006-12 79

Figure 36: Growth drivers and resistors by geography, sales ($m),
2006-12 80

Figure 37: US dependency vs. peer set, % total sales, 2006 81

Figure 38: US dependency vs. peer set, % total sales, 2012 82

Figure 39: Molecule type sales breakdown ($m), 2006-12 84

Figure 40: Growth drivers and resistors by molecule type, sales
($m), 2006-12 85

Figure 41: Biologics dependency vs. peer set, % total sales, 2006
86

Figure 42: Biologics dependency vs. peer set, % total sales, 2012
87

Figure 43: Mechanisms by which current treatments reduce
intraocular pressure 94

Figure 44: US glaucoma drug sales by class, 2002-06 ($m) 95

Figure 45: Quarterly US Alphagan franchise sales, 2001-07 ($m) 96

Figure 46: Quarterly M5EU Alphagan franchise sales, 2002-07 ($m)
99

Figure 47: Prostaglandin class sales in the US, 2002-06 ($m) 110

Figure 48: M5EU quarterly prostaglandin class sales, 2002-07 ($m)
112

Figure 49: IMS vs. company-reported prescription pharmaceutical
sales discrepancy ($m), 2006 132

Figure 50: IMS vs. company-reported prescription pharmaceutical
sales forecast growth rates (%), 2006-12 133

To order that report:

www.reportlinker.com/p073696/Allergan-Inc-PharmaVitae-Profile.html

For more information, contact Nicolas by email
nbo@reportlinker.com , or by phone +33 4 37 65 17 03.

More market research reports?

Go to www.reportlinker.com

Reportlinker.com
Nicolas, +33 4 37 65 17 03
nbo@reportlinker.com

Copyright Business Wire 2008